1. Proteomics: addressing the challenges of multiple myeloma

    Multiple myeloma (MM) is a malignancy of terminally differentiated B-lymphocytes that accounts for ∼13% of all hematologic cancers. Despite a wealth of knowledge describing the molecular biology of MM as well as significant advances in therapeutics, this disease remains incurable.

1 Item

To Top